Edition:
United Kingdom

Indivior PLC (INDV.L)

INDV.L on London Stock Exchange

107.95GBp
22 Mar 2019
Change (% chg)

0.85 (+0.79%)
Prev Close
107.10
Open
107.95
Day's High
109.70
Day's Low
105.95
Volume
2,231,345
Avg. Vol
3,502,500
52-wk High
504.60
52-wk Low
75.48

Latest Key Developments (Source: Significant Developments)

Indivior Announces Launch Of Perseris For Treatment Of Schizophrenia In Adults
Wednesday, 27 Feb 2019 

Feb 27 (Reuters) - Indivior PLC ::INDIVIOR ANNOUNCES LAUNCH OF PERSERIS™ (RISPERIDONE) FOR THE TREATMENT OF SCHIZOPHRENIA IN ADULTS.INDIVIOR PLC - LAUNCH OF ONCE-MONTHLY PERSERIS (RISPERIDONE) FOR EXTENDED-RELEASE INJECTABLE SUSPENSION IN UNITED STATES.  Full Article

Indivior Launches PERSERIS In The U.S.
Wednesday, 27 Feb 2019 

Feb 27 (Reuters) - Indivior PLC ::INDIVIOR LAUNCHES PERSERIS (RISPERIDONE).ANNOUNCES LAUNCH OF PERSERIS (RISPERIDONE) FOR TREATMENT OF SCHIZOPHRENIA IN ADULTS.LAUNCH OF ONCE-MONTHLY PERSERIS FOR EXTENDED-RELEASE INJECTABLE SUSPENSION IN UNITED STATES.  Full Article

Indivior Says Sublocade New Drug Submissions Made In Australia And Europe
Thursday, 14 Feb 2019 

Feb 14 (Reuters) - Indivior PLC ::INDIVIOR PLC - SUBLOCADE NEW DRUG SUBMISSIONS MADE IN AUSTRALIA AND EUROPE.INDIVIOR PLC - SEES 2019 OPERATING EXPENSES (SG&A AND RESEARCH AND DEVELOPMENT COMBINED) OF APPROXIMATELY $440M TO $460M, EXCLUDING EXCEPTIONAL ITEMS.INDIVIOR PLC - SEES ABOUT $140M OF ACTUAL ADJUSTED. OPEXSAVINGS BY END OF FY 2019 VERSUS. FY 2017 BASELINE.INDIVIOR PLC - VOLUNTARILY REPAID $235M OF TERM LOANS; $243M REMAINS OUTSTANDING.INDIVIOR PLC - READY TO LAUNCH AUTHORIZED GENERIC OF BUPRENORPHINE/NALOXONE SUBLINGUAL FILM.INDIVIOR PLC - CONTINUE TO ASSERT INTELLECTUAL PROPERTY AGAINST ANDA FILERS.INDIVIOR PLC - TARGETING APPROPRIATE HCPS WITH HIGH VOLUME LAI PRACTICES FOR PERSERIS IN 2019.  Full Article

Indivior Says FY Net Revenue Down 8 Pct To $1.01 Bln
Thursday, 14 Feb 2019 

Feb 14 (Reuters) - Indivior PLC ::INDIVIOR PLC - FINAL RESULTS.INDIVIOR PLC - FY NET REVENUE OF $1,005M, A DECREASE OF 8% VERSUS PRIOR YEAR.INDIVIOR PLC - FY OPERATING PROFIT WAS $292M (FY 2017: $193M).INDIVIOR PLC - U.S. SUBOXONE FILM MARKET SHARE AVERAGED AND EXITED FY 2018 AT 53%..INDIVIOR- TO LAUNCH AUTHORIZED GENERIC OF SUBOXONE FILM UPON CONFIRMATION OF LAUNCH OF GENERIC BUPRENORPHINE/NALOXONE SUBLINGUAL FILM PRODUCTS.INDIVIOR PLC - IMPLEMENTED KEY ELEMENTS OF ITS CONTINGENCY PLAN TO HELP OFFSET SUBSTANTIAL AND MATERIAL NEAR-TERM IMPACT TO NET REVENUE.INDIVIOR PLC - INDIVIOR IS UNABLE TO PROVIDE FY 2019 NET REVENUE AND NET INCOME GUIDANCE AT THIS TIME.INDIVIOR PLC - SEES SUBLOCADE NET REVENUE OF $50M TO $70M FOR FY 2019.INDIVIOR PLC - SEES FY 2019 OPERATING EXPENSES (SG&A AND RESEARCH AND DEVELOPMENT COMBINED) OF APPROXIMATELY $440M TO $460M.INDIVIOR -INTENDS TO PROVIDE FY19 NET REVENUE, NET INCOME GUIDANCE ONCE TOTAL U.S. BUPRENORPHINE/NALOXONE SUBLINGUAL FILM MARKET DYNAMICS ARE CLEARER.INDIVIOR PLC - "AS WE ENTER FY 2019, WE ASSUME WE FACE IMMINENT "AT-RISK" LAUNCH OF GENERIC RIVALS TO SUBOXONE FILM IN U.S".INDIVIOR PLC - FY SUBLOCADE NET REVENUES WERE $12M, INCLUDING $7M IN Q4 2018.INDIVIOR - CONTINUES IN ADVANCED DISCUSSIONS WITH U.S. DEPARTMENT OF JUSTICE ABOUT A POSSIBLE RESOLUTION TO ITS INVESTIGATIONS.INDIVIOR PLC - AUTHORIZED GENERIC OF SUBOXONE FILM LAUNCH EXPECTED TO GENERATE AN AMOUNT OF NET REVENUE IN RANGE OF TENS OF U.S.$ MILLIONS.  Full Article

Indivior Enters Into Agreement With Alvogen
Monday, 4 Feb 2019 

Feb 4 (Reuters) - Indivior Plc ::INDIVIOR ENTERS INTO AGREEMENT WITH ALVOGEN.ENTERED INTO AN AGREEMENT WITH ALVOGEN PINE BROOK LLC.TO CONTINUE TO PURSUE INFRINGEMENT CASES AGAINST ALVOGEN, APPEAL OF U.S. COURT'S NON-INFRINGEMENT DECISION RELATED TO U.S. PATENT 8,603,514.TO CONTINUE PURSUING INFRINGEMENT CASES INCLUDING DISTRICT COURT LITIGATION OF MORE RECENTLY LISTED ORANGE BOOK PATENTS FOR SUBOXONE FILM.DEAL ENJOINS ALVOGEN FROM SALE IN U.S. OF GENERIC BUPRENORPHINE, NALOXONE SUBLINGUAL FILM UNLESS COURT VACATES INJUNCTION AGAINST DR. REDDY'S.  Full Article

Indivior To Sell Rights On Sai Bo Song Tablet In China For $122.5 Mln
Monday, 4 Feb 2019 

Feb 4 (Reuters) - Indivior Plc ::INDIVIOR TO DIVEST INTEREST IN CHINA.DEAL FOR TOTAL CONSIDERATION OF UP TO $122.5 MILLION.ENTERED INTO A DEFINITIVE AGREEMENT TO DIVEST ITS RIGHTS RELATED TO SAI BO SONG TABLET IN CHINA.TERMS OF TRANSACTION INCLUDE A SIGNING PAYMENT OF $1.5 MILLION.TERMS OF TRANSACTION ALSO INCLUDE $3.5 MILLION UPON DESIGNATION OF SAI BO SON TABLET AS CLASS II PSYCHOTROPIC DRUG BY CHINESE REGULATORS.TO DIVEST TO SAI BO SONG TABLET IN CHINA TO ZHEJIANG PUKANG BIOTECHNOLOGY CO LTD .  Full Article

Aquestive Therapeutics Granted Temporary Restraining Order Against Alvogen
Friday, 25 Jan 2019 

Jan 25 (Reuters) - Aquestive Therapeutics Inc ::AQUESTIVE THERAPEUTICS GRANTED TEMPORARY RESTRAINING ORDER (TRO) AGAINST ALVOGEN.AQUESTIVE THERAPEUTICS - TRO TO REMAIN IN PLACE PENDING HEARING ON PRELIM. INJUNCTION MOTION PREVIOUSLY FILED BY CO, INDIVIOR.AQUESTIVE THERAPEUTICS - TRO ENJOINS ALVOGEN FROM INITIATING ANY LAUNCH ACTIVITIES RELATED TO ITS GENERIC BUPRENORPHINE/NALOXONE SUBLINGUAL FILM.AQUESTIVE THERAPEUTICS INC - HEARING ON PI MOTION IS SCHEDULED WITH DISTRICT COURT ON FEBRUARY 7, 2019.  Full Article

Indivior Says Granted Temporary Restraining Order For Buprenorphine And Naloxone Sublingual Film Product
Friday, 25 Jan 2019 

Jan 25 (Reuters) - Indivior PLC ::INDIVIOR PLC - INDIVIOR GRANTED TEMPORARY RESTRAINING ORDER.INDIVIOR - TRO CONCERNING BUPRENORPHINE AND NALOXONE SUBLINGUAL FILM PRODUCT WILL REMAIN IN PLACE UNTIL FEBRUARY 7, 2019.INDIVIOR - U.S. COURT GRANTED CO TEMPORARY ORDER PREVENTING ALVOGEN PINE BROOK FROM LAUNCHING GENERIC BUPRENORPHINE,NALOXONE SUBLINGUAL FILM PRODUCT.  Full Article

Indivior Says Expects More Players In The Generic Suboxone Market - Conf Call
Tuesday, 18 Dec 2018 

Dec 18 (Reuters) - Indivior PLC ::INDIVIOR SAYS EXPECTS MORE PLAYERS IN THE GENERIC SUBOXONE MARKET WITH POTENTIAL FOR THREE PLAYERS, CO’S AUTHORIZED GENERIC BEING FOURTH - CONF CALL.INDIVIOR SAYS THERE HAS BEEN INITIAL NET REVENUE FROM PERSERIS IN FY 2018, MATERIAL CONTRIBUTION EXPECTED TO BEGIN IN 2019 AND BEYOND - CONF CALL.  Full Article

Indivior Says Federal Court Declines Immediate Issue Of Mandate
Wednesday, 12 Dec 2018 

Dec 12 (Reuters) - Indivior PLC ::FEDERAL COURT DECLINES IMMEDIATE ISSUE OF MANDATE.COURT OF APPEALS FOR FEDERAL CIRCUIT DECLINES TO IMMEDIATELY ISSUE MANDATE AFTER PRELIMINARY INJUNCTION RULING.U.S. COURT DENIED DR. REDDY'S MOTION TO IMMEDIATELY ISSUE MANDATE FOLLOWING CAFC'S RULING VACATING PRELIMINARY INJUNCTION.CAFC ALSO ORDERED THAT ANY PETITION FOR REHEARING BE SUBMITTED ON OR BEFORE DECEMBER 20, 2018.REDDY'S WILL REMAIN ENJOINED FROM RESUMING "AT-RISK" U.S. LAUNCH OF GENERIC BUPRENORPHINE-NALOXONE SUBLINGUAL FILM TILL AFTER MANDATE ISSUES.  Full Article

Photo

Banks lift FTSE 100 as trade optimism reigns; Ted Baker rallies

Britain's FTSE 100 rose on Monday as financial firms gained on reports China and the United States were nearing a trade deal, a stronger dollar helped exporter stocks, while clothing retailer Ted Baker advanced after CEO Ray Kelvin's resignation.